1. De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold
- Author
-
Dawn K. Stetsko, Dominique Besse, Francois Caussade, Eric Nicolai, Brett R. Beno, Stacey Skala, Michele Launay, Dominique Potin, ChiehYing J. Chang, Suzanne J. Suchard, Patrice Malabre, Edwin J. Iwanowicz, Maud Fabreguette, Gordon Todderud, Daniel L. Cheney, Steven Sheriff, Joel C. Barrish, T. G. Murali Dhar, and Diane Hollenbaugh
- Subjects
Scaffold ,Endothelium ,Clinical Biochemistry ,Molecular Conformation ,Pharmaceutical Science ,Hydantoin ,chemical and pharmacologic phenomena ,Biochemistry ,Inhibitory Concentration 50 ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,medicine ,Humans ,Beta (finance) ,Molecular Biology ,Inflammation ,Bicyclic molecule ,Hydantoins ,Organic Chemistry ,hemic and immune systems ,Adhesion ,Bridged Bicyclo Compounds, Heterocyclic ,Intercellular Adhesion Molecule-1 ,Lymphocyte Function-Associated Antigen-1 ,In vitro ,Cell biology ,medicine.anatomical_structure ,chemistry ,Design synthesis ,Drug Design ,Molecular Medicine ,HeLa Cells ,Protein Binding - Abstract
LFA-1 (leukocyte function-associated antigen-1), is a member of the beta(2)-integrin family and is expressed on all leukocytes. The LFA-1/ICAM interaction promotes tight adhesion between activated leukocytes and the endothelium, as well as between T cells and antigen-presenting cells. Evidence from both animal models and clinical trials provides support for LFA-1 as a target in several different inflammatory diseases. This paper describes the de novo design, synthesis and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.
- Published
- 2005
- Full Text
- View/download PDF